221 related articles for article (PubMed ID: 27826881)
21. Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Blevins TC; Farooki A
Postgrad Med; 2017 Jan; 129(1):159-168. PubMed ID: 27894216
[TBL] [Abstract][Full Text] [Related]
22. In brief: Canagliflozin and lower limb amputations.
Med Lett Drugs Ther; 2020 Sep; 62(1607):152. PubMed ID: 32960870
[No Abstract] [Full Text] [Related]
23. Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.
Johnsson K; Johnsson E; Mansfield TA; Yavin Y; Ptaszynska A; Parikh SJ
Postgrad Med; 2016 May; 128(4):346-55. PubMed ID: 26878357
[TBL] [Abstract][Full Text] [Related]
24. The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Imprialos KP; Stavropoulos K; Doumas M; Karagiannis A; Athyros VG
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1251-1261. PubMed ID: 28829209
[TBL] [Abstract][Full Text] [Related]
25. [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
Simonyi G
Orv Hetil; 2012 May; 153(18):695-701. PubMed ID: 22547464
[TBL] [Abstract][Full Text] [Related]
26. Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
Rizos EC; Elisaf MS
Curr Pharm Des; 2014; 20(22):3647-56. PubMed ID: 24040872
[TBL] [Abstract][Full Text] [Related]
27. Initiation of dapagliflozin and treatment-emergent fractures.
Toulis KA; Bilezikian JP; Thomas GN; Hanif W; Kotsa K; Thayakaran R; Keerthy D; Tahrani AA; Nirantharakumar K
Diabetes Obes Metab; 2018 Apr; 20(4):1070-1074. PubMed ID: 29193543
[TBL] [Abstract][Full Text] [Related]
28. Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Desai M; Yavin Y; Balis D; Sun D; Xie J; Canovatchel W; Rosenthal N
Diabetes Obes Metab; 2017 Jun; 19(6):897-900. PubMed ID: 28083972
[TBL] [Abstract][Full Text] [Related]
29. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
30. Effects of sodium glucose co-transporter 2 inhibitors on the kidney.
de Albuquerque Rocha N; Neeland IJ; McCullough PA; Toto RD; McGuire DK
Diab Vasc Dis Res; 2018 Sep; 15(5):375-386. PubMed ID: 29963920
[TBL] [Abstract][Full Text] [Related]
31. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.
Avogaro A; Giaccari A; Fioretto P; Genovese S; Purrello F; Giorgino F; Del Prato S
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):763-772. PubMed ID: 28431476
[TBL] [Abstract][Full Text] [Related]
32. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
Tang H; Li D; Zhang J; Li Y; Wang T; Zhai S; Song Y
Diabetes Obes Metab; 2017 Aug; 19(8):1106-1115. PubMed ID: 28240446
[TBL] [Abstract][Full Text] [Related]
33. In brief: ketoacidosis with SGLT2 inhibitors.
Med Lett Drugs Ther; 2015 Jun; 57(1471):94. PubMed ID: 26079766
[No Abstract] [Full Text] [Related]
34. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
Ahmed M; McKenna MJ; Crowley RK
Endocr Pract; 2017 Apr; 23(4):506-508. PubMed ID: 28437153
[TBL] [Abstract][Full Text] [Related]
35. Sodium glucose co-transporter 2 inhibitors: a novel approach to the management of type 2 diabetes mellitus.
Davis CS; Fleming JW; Warrington LE
J Am Assoc Nurse Pract; 2014 Jul; 26(7):356-63. PubMed ID: 24895099
[TBL] [Abstract][Full Text] [Related]
36. Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.
Angelopoulos TP; Doupis J
Adv Ther; 2014 Jun; 31(6):579-91. PubMed ID: 24972995
[TBL] [Abstract][Full Text] [Related]
37. Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.
Scheen AJ
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1303-1316. PubMed ID: 28984487
[TBL] [Abstract][Full Text] [Related]
38. [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
Lindberg MJ; Kristensen FB; Yildiz A
Ugeskr Laeger; 2016 Nov; 178(47):. PubMed ID: 27908315
[TBL] [Abstract][Full Text] [Related]
39. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266
[No Abstract] [Full Text] [Related]
40. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?
Goncalves E; Bell DSH
Diabetes Obes Metab; 2017 Jun; 19(6):909-911. PubMed ID: 28176440
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
